Phase I clinical evaluation of ^99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer.

ABSTRACT: The determination of tumor human epidermal growth factor receptor type 2 (HER2) status is of increasing importance with the recent approval of more efficacious HER2-targeted treatments. There is a lack of suitable methods for clinical in vivo HER2 expression assessment. Affibody molecules are small affinity proteins ideal for imaging detection of receptors, which are engineered using a small (molecular weight 6.5 kDa) nonimmunoglobulin scaffold. Labeling of Affibody molecules with positron emitters enabled the development of sensitive and specific agents for molecular imaging. The development of probes for SPECT would permit the use of Affibody-based imaging in regions where PET is not available. In this first-in-human study, we evaluated the safety, biodistribution, and dosimetry o

SUBMITTER: Bragina O 

PROVIDER: S-EPMC10526658 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature